Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.

Shares of Hims & Hers (NYSE:HIMS) fell 14% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer considered to be in short supply in the U.S. Certain doses of ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Investors with a lot of money to spend have taken a bearish stance on Hims & Hers Health (NYSE:HIMS). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term ...

View Hims & Hers Health, Inc. (HIMS) current and estimated P/E ratio data provided by Seeking Alpha.

Shares of social media companies Reddit (RDDT) and Snap (SNAP) are surging after better-than-expected quarterly results ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...